Nothing Special   »   [go: up one dir, main page]

ATE511852T1 - Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin - Google Patents

Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin

Info

Publication number
ATE511852T1
ATE511852T1 AT03787049T AT03787049T ATE511852T1 AT E511852 T1 ATE511852 T1 AT E511852T1 AT 03787049 T AT03787049 T AT 03787049T AT 03787049 T AT03787049 T AT 03787049T AT E511852 T1 ATE511852 T1 AT E511852T1
Authority
AT
Austria
Prior art keywords
alpha
thymosine
protection against
radiation damage
against radiation
Prior art date
Application number
AT03787049T
Other languages
English (en)
Inventor
Alfred Rudolph
Cynthia Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE511852T1 publication Critical patent/ATE511852T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT03787049T 2002-11-25 2003-11-25 Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin ATE511852T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42874602P 2002-11-25 2002-11-25
PCT/US2003/037469 WO2004048971A1 (en) 2002-11-25 2003-11-25 Methods of protecting against radiation damage using alpha thymosin

Publications (1)

Publication Number Publication Date
ATE511852T1 true ATE511852T1 (de) 2011-06-15

Family

ID=32393452

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03787049T ATE511852T1 (de) 2002-11-25 2003-11-25 Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin

Country Status (16)

Country Link
US (1) US7897567B2 (de)
EP (1) EP1570269B1 (de)
JP (1) JP2006507349A (de)
KR (1) KR20050086819A (de)
CN (1) CN100501400C (de)
AT (1) ATE511852T1 (de)
AU (1) AU2003295838B2 (de)
BR (2) BR0316646A (de)
CA (1) CA2506893A1 (de)
EA (1) EA008059B1 (de)
MX (1) MXPA05005538A (de)
NO (1) NO330217B1 (de)
NZ (1) NZ540847A (de)
PL (1) PL377376A1 (de)
UA (1) UA81932C2 (de)
WO (1) WO2004048971A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
US20060246057A1 (en) * 2003-07-18 2006-11-02 Regenerx Biopharmaceuticals, Inc Treatment or prevention of damage due to radiation exposure
JP5307559B2 (ja) * 2006-03-07 2013-10-02 バイオテンプト ビー．ブイ． 放射線障害の制御の為にペプチドを使用する方法
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195980A (en) * 1966-08-24 1970-06-24 Univ Yeshiva Hormone-Like Preparations Derived from Thymus Gland and Methods of Producing the Same.
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
TW252045B (de) * 1993-10-07 1995-07-21 Allan L Goldstein
ES2174915T3 (es) 1993-11-10 2002-11-16 Enzon Inc Productos de conjugacion mejorados de un interferon con un polimero.
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1303713A (zh) 2000-01-07 2001-07-18 广州暨南大学医药生物技术研究开发中心 预防和治疗辐射损伤的保健组合物
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
ATE537845T1 (de) 2000-10-31 2012-01-15 Pr Pharmaceuticals Inc Verfahren zur herstellung von formulierungen zur verbesserten abgabe von bioaktiven molekülen
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide

Also Published As

Publication number Publication date
CN1717587A (zh) 2006-01-04
UA81932C2 (uk) 2008-02-25
BRPI0316646A8 (pt) 2018-04-24
NO330217B1 (no) 2011-03-07
JP2006507349A (ja) 2006-03-02
CA2506893A1 (en) 2004-06-10
EP1570269A1 (de) 2005-09-07
EA008059B1 (ru) 2007-02-27
AU2003295838A1 (en) 2004-06-18
KR20050086819A (ko) 2005-08-30
NZ540847A (en) 2006-07-28
EA200500773A1 (ru) 2005-12-29
NO20052943D0 (no) 2005-06-16
EP1570269B1 (de) 2011-06-08
NO20052943L (no) 2005-08-09
PL377376A1 (pl) 2006-02-06
AU2003295838B2 (en) 2008-05-22
EP1570269A4 (de) 2008-09-10
US7897567B2 (en) 2011-03-01
MXPA05005538A (es) 2005-08-16
WO2004048971A1 (en) 2004-06-10
BR0316646A (pt) 2005-10-11
US20060166877A1 (en) 2006-07-27
CN100501400C (zh) 2009-06-17

Similar Documents

Publication Publication Date Title
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
DE69736981D1 (de) In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
HK1068545A1 (en) Transdermal patch for administering fentanyl
DE502005003025D1 (de) Solarzellenanordnung sowie verfahren zum verschalten eines solarzellenstrings
DK1280552T3 (da) Fremgangsmåde til behandling af hudcancer ved anvendelse af præparater der omfatter en endothelin B-receptor-inhibitor
DE122011100032I1 (de) Verwendung von n-substituierten pyridonen als tumornekrose-faktor alpha hemmer.
HRP20050436B1 (hr) Kinolinil-pirolpirazoli
ATE511852T1 (de) Verfahren zum schutz vor strahlungsschäden unter verwendung von alpha-thymosin
ATE483467T1 (de) Verfahren zum schutz vor strahlung mit flagellin
ATE298249T1 (de) Verfahren zur behandlung einer fibrose unter verwendung eines antagonisten der integrin alpha- 4 untereinheit
ATE314394T1 (de) Verfahren und zusammensetzungen zur stimulation und inhibition der aktivität von tgf-beta
DE69601026D1 (de) Verwendung eines Antagonisten von TNF-alpha zur Behandlung von Hautrötungen neurogenen Ursprungs
ATE493980T1 (de) Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
DE69722809D1 (de) Behandlung von stressinduzierten hautkrankheiten unter verwendung von corticoliberin (crh)-antagonisten und inhibitoren der hautmastzell-degranulation
DK1509523T3 (da) Triazaspiro-forbindelser anvendelige for at behandle eller forhindre smerte
DE60126802D1 (de) Cyclopeptide, verfahren zu ihrer herstellung und ihre verwendung zur hemmung oder stimulierung von angiogenese
DK1554374T3 (da) Fremgangsmåde til storskala T-lymfocytdyrkning i et homogent system
DE502004010751D1 (de) Verfahren und vorrichtung zum magnetronsputtern
ATE516040T1 (de) Zusammensetzung und verwendung zur vorbeugung oder behandlung von stomatitis
ATA216087A (de) Verfahren zum schutz eines tieres gegen coccidiose
ATE448579T1 (de) Verfahren zur inertisierung der anoden von brennstoffzellen
ATE467422T1 (de) Behandlung von aspergillus-infektionen mit thymosin alpha 1
UA83628C2 (ru) Способ защиты эндотелиальных и эпителиальных клеток во время трансплантации алогенных стволовых клеток
FR2873698B1 (fr) Nouveau peptide et composition pharmaceutique le contenant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties